Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 1
2019 2
2020 3
2021 4
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.
Pérez-Carretero C, González-Gascón-Y-Marín I, Rodríguez-Vicente AE, Quijada-Álamo M, Hernández-Rivas JÁ, Hernández-Sánchez M, Hernández-Rivas JM. Pérez-Carretero C, et al. Among authors: quijada alamo m. Diagnostics (Basel). 2021 May 10;11(5):853. doi: 10.3390/diagnostics11050853. Diagnostics (Basel). 2021. PMID: 34068813 Free PMC article. Review.
From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.
González-Gascón-Y-Marín I, Muñoz-Novas C, Rodríguez-Vicente AE, Quijada-Álamo M, Hernández-Sánchez M, Pérez-Carretero C, Ramos-Ascanio V, Hernández-Rivas JÁ. González-Gascón-Y-Marín I, et al. Among authors: quijada alamo m. Cancers (Basel). 2021 Apr 8;13(8):1782. doi: 10.3390/cancers13081782. Cancers (Basel). 2021. PMID: 33917885 Free PMC article. Review.
The Five "Ws" of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When.
González-Gascón-Y-Marín I, Ballesteros-Andrés M, Martínez-Flores S, Rodríguez-Vicente AE, Pérez-Carretero C, Quijada-Álamo M, Rodríguez-Sánchez A, Hernández-Rivas JÁ. González-Gascón-Y-Marín I, et al. Among authors: quijada alamo m. Cancers (Basel). 2023 Sep 2;15(17):4391. doi: 10.3390/cancers15174391. Cancers (Basel). 2023. PMID: 37686667 Free PMC article. Review.
Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M, Pérez-Carretero C, Hernández-Sánchez M, Rodríguez-Vicente AE, Herrero AB, Hernández-Sánchez JM, Martín-Izquierdo M, Santos-Mínguez S, Del Rey M, González T, Rubio-Martínez A, García de Coca A, Dávila-Valls J, Hernández-Rivas JÁ, Parker H, Strefford JC, Benito R, Ordóñez JL, Hernández-Rivas JM. Quijada-Álamo M, et al. Clin Transl Med. 2021 Feb;11(2):e304. doi: 10.1002/ctm2.304. Clin Transl Med. 2021. PMID: 33634999 Free PMC article.
TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
Pérez-Carretero C, Hernández-Sánchez M, González T, Quijada-Álamo M, Martín-Izquierdo M, Santos-Mínguez S, Miguel-García C, Vidal MJ, García-De-Coca A, Galende J, Pardal E, Aguilar C, Vargas-Pabón M, Dávila J, Gascón-Y-Marín I, Hernández-Rivas JÁ, Benito R, Hernández-Rivas JM, Rodríguez-Vicente AE. Pérez-Carretero C, et al. Among authors: quijada alamo m. Am J Hematol. 2022 Jul;97(7):903-914. doi: 10.1002/ajh.26578. Epub 2022 May 9. Am J Hematol. 2022. PMID: 35472012 Free article.
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.
Quijada-Álamo M, Hernández-Sánchez M, Rodríguez-Vicente AE, Pérez-Carretero C, Rodríguez-Sánchez A, Martín-Izquierdo M, Alonso-Pérez V, García-Tuñón I, Bastida JM, Vidal-Manceñido MJ, Galende J, Aguilar C, Queizán JA, González-Gascón Y Marín I, Hernández-Rivas JÁ, Benito R, Ordóñez JL, Hernández-Rivas JM. Quijada-Álamo M, et al. Blood Cancer J. 2021 Jul 9;11(7):127. doi: 10.1038/s41408-021-00520-5. Blood Cancer J. 2021. PMID: 34244476 Free PMC article.
CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase.
Hernández-Sánchez M, Kotaskova J, Rodríguez AE, Radova L, Tamborero D, Abáigar M, Plevova K, Benito R, Tom N, Quijada-Álamo M, Bikos V, Martín AÁ, Pal K, García de Coca A, Doubek M, López-Bigas N, Hernández-Rivas JM, Pospisilova S. Hernández-Sánchez M, et al. Among authors: quijada alamo m. Leukemia. 2019 Feb;33(2):518-558. doi: 10.1038/s41375-018-0255-1. Epub 2018 Sep 12. Leukemia. 2019. PMID: 30209402 Free PMC article. No abstract available.
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo M, Hernández-Sánchez M, Alonso-Pérez V, Rodríguez-Vicente AE, García-Tuñón I, Martín-Izquierdo M, Hernández-Sánchez JM, Herrero AB, Bastida JM, San Segundo L, Gruber M, García JL, Yin S, Ten Hacken E, Benito R, Ordóñez JL, Wu CJ, Hernández-Rivas JM. Quijada-Álamo M, et al. Leukemia. 2020 Jun;34(6):1599-1612. doi: 10.1038/s41375-020-0714-3. Epub 2020 Jan 23. Leukemia. 2020. PMID: 31974435 Free PMC article.
DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains.
Hernández-Sánchez M, Rodríguez-Vicente AE, González-Gascón Y Marín I, Quijada-Álamo M, Hernández-Sánchez JM, Martín-Izquierdo M, Hernández-Rivas JÁ, Benito R, Hernández-Rivas JM. Hernández-Sánchez M, et al. Among authors: quijada alamo m. Exp Hematol. 2019 Apr;72:9-13. doi: 10.1016/j.exphem.2019.02.003. Epub 2019 Feb 23. Exp Hematol. 2019. PMID: 30807786 Free article.
15 results